Team
Thericon Augmented imaging
See Everything you need
Thericon is the first to bring multiparametric imaging to the operating theater
This allows for displaying of previously invisible tissue properties together with standard color images on a single screen.
The wealth of this diagnostic information and its intuitive presentation allows for faster and more accurate surgery results.
Our Vision
IMPROVING THE PROGNOSIS OF 550,000 PATIENTS DIAGNOSED WITH BLADDER CANCER EACH YEAR BY MAKING CANCER STAND OUT
Our mission is to improve the success of surgeries by enabling surgeons better to distinguish different tissue types and identify malignant lesions. Our proprietary technology enables multiparametric endoscopy where various structural and functional images are provided simultaneously.
The first application of our real-time multispectral imaging technology is in transurethral resections of bladder tumor (TURBT), where we expect it will contribute to reducing disease recurrence and minimizing collateral tissue damage.
The case
Approximately 200.000 people die every year worldwide due to bladder cancer. Among men, bladder cancer is the 5th most common cancer worldwide, accounting for 6.2% of all cancers. Every year in US and EU out of 600.000 surgical cancer resections, 300.000 cancer recurrences happen.
The ISSUE
A visual image of bladder tumors requires ample experience for interpretation. Especially small tumors are extremely difficult to identify, resulting in false negative interpretation in ~20% of the cases, thus leading to remaining tumor tissue in the patient. This can cause disease recurrence, leading to re-surgery or even death.
The cure
rMSI technology will allow optically and intuitively differentiating whether tissue is malignant or healthy. Surgeons may thus for the first time be able to greatly improve the success rate of operation, improve post-surgery prognosis and in the long term increase the average life expectancy.
Science and technology from Mannheim, Germany
Market Trends
Economics
The global endoscopic equipment market volume is expected to grow with an CAGR of 6.6% annually. It is estimated to reach 23.3 billion EUR in 2019 and projected to reach a value of 34.8 billion EUR by 2024.
An average university hospital in Germany is performing about 500 transurethral resections of bladder tumour (TURBT) every year on 200 patients, of which about 30% are new cases. An expected reduction of recurrence by 20% is estimated to result in 7% (or 350 €) cost reduction per patient per year.
0
%
market growth rate annually
0
k EUR
annual savings per hospital
0
%
of doctors recommend rMSI
see for yourself
rMSI technology combines standard white light image with enhanced vascular contrast and photodynamic diagnosis in one image and offers unprecedented identification of suspicious lesions.
Frank Sodha
Chief Executive Officer
Experience: entrepreneur, investor, consultant, builder in the Medical Device and Pharmaceutical industries with a strong track record.
Competencies: medical devices, contract manufacturing, pharmaceuticals, M&A, technology transfer, strategic management, startups, business consulting.
Dr. Nikolaos Deliolanis
Chief Scientific Officer
Experience: 16 years’ of R&D in biomedical optics and eight years in a management position. PhD in physics.
Competencies: medical engineering and imaging, clinical studies, management, business and business development.
Dr. Bartek Grychtol
Chief Operating Officer
Experience: 18 years’ of research in medical imaging. R&D consultant for medical device startups. EngD in medical devices.
Competencies: biomedical engineering, algorithm development, software engineering and agile management.
Dr. Steffen Schabel
Chief Marketing and Sales Officer
Experience: entrepreneur, business angel, sales, marketing, customer care, consultant, market access, medical device expert.
Competencies: medical devices, sales operations, sales management, marketing, market development, product launch, customer service, startups.
Testimonials
What Doctors say
5/5
"The performance of rMSI technology is impressively demonstrated by zero false negative diagnoses, utilizing multi parameter imaging, crunching down the probability of false negative diagnosis at least one order of magnitude."
Dr. Deliolanis
Physician
5/5
"The main benefits given by rMSI are operational success rate due to better tissue classification, and a higher reliability diagnosis. Furthermore, a more intuitive visualisation, paired with comfortable handling improve the ease-of-use."
Dr. Grychtol
Urologist
5/5
"This multiparametric approach probably represents the most pioneering concept, thus greatly improving patient prognosis and wellbeing. The computer-generated images guide the surgeon along the operation, increasing the success rate."
Dr. Rother
Assistant
Get involved where it matters
Our mission is to help patients suffering from urethral cancer. Connect with us and make a real difference to the life of those in need.
Get in touch
We are looking for stakeholders, investors and partners to bring our product to the market.
In cooperation with
